GlassScriptPhysician profile
Fred Allan Liebowitz
NPI 1801892633
$6,429.34
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $507 · 2021: $618 · 2022: $591 · 2023: $1,269 · 2024: $839 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,566.28 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $1,554.42 | 2020-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $633.57 | 2022-2025 | Intracept, General - Pain Management |
| Merck Sharp & Dohme LLC | $310.09 | 2019-2023 | Belsomra |
| Pfizer INC. | $262.89 | 2019-2023 | |
| Medtronic, INC. | $254.81 | 2021 | |
| Tersera Therapeutics LLC | $154.57 | 2019-2024 | Prialt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.85 | 2022-2025 | Relistor |
| Vertos Medical, INC. | $144.22 | 2023 | Mild Device Kit |
| Curonix LLC | $141.76 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Relievant Medsystems, INC. | $139.96 | 2023 | Intracept |
| Spinal Simplicity, LLC | $122.59 | 2023 | Ha Minuteman G3-R |
| Biodelivery Sciences International, INC. | $104.81 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $96.14 | 2023-2024 | Quviviq |
| Si-Bone, INC. | $91.68 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $84.26 | 2019-2024 | Zubsolv |
| Scilex Pharmaceuticals INC. | $73.50 | 2019-2023 | Ztlido |
| Indivior INC. | $70.48 | 2021-2023 | Sublocade |
| Abbvie INC. | $58.12 | 2022-2023 | |
| Ibsa Pharma INC. | $54.96 | 2021-2024 | Licart, Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $50.21 | 2019-2024 | Austedo Xr |
| Nevro Corp. | $47.68 | 2019-2023 | Senza |
| Averitas Pharma INC. | $47.31 | 2023-2025 | Qutenza |
| Lilly USA, LLC | $36.67 | 2022-2024 | Emgality |
| Avanos Medical | $33.10 | 2019 | |
| Lundbeck LLC | $31.87 | 2025 | Vyepti |
| Eisai INC. | $22.69 | 2021 | |
| Forte Bio-Pharma LLC | $22.58 | 2024 | Prolate, Nalocet |
| Carolina Liquid Chemistries Corp | $18.46 | 2019 | |
| Uswm, LLC | $18.16 | 2022 | |
| Horizon Therapeutics Plc | $15.39 | 2021 | |
| Almatica Pharma LLC | $13.26 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Liebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.